ATF1 is altered in 66.67% of clear cell sarcoma of soft tissue patients [2].

ATF1 is an inclusion eligibility criterion in 1 clinical trial for clear cell sarcoma of soft tissue, of which 1 is open and 0 are closed. Of the trial that contains ATF1 status and clear cell sarcoma of soft tissue as inclusion criteria, 1 is phase 2 (1 open) [3].

AXL is an inclusion eligibility criterion in 1 clinical trial for clear cell sarcoma of soft tissue, of which 1 is open and 0 are closed. Of the trial that contains AXL status and clear cell sarcoma of soft tissue as inclusion criteria, 1 is phase 2 (1 open) [3].

EWSR1 is altered in 90.91% of clear cell sarcoma of soft tissue patients [2].

EWSR1 is an inclusion eligibility criterion in 2 clinical trials for clear cell sarcoma of soft tissue, of which 2 are open and 0 are closed. Of the trials that contain EWSR1 status and clear cell sarcoma of soft tissue as inclusion criteria, 2 are phase 2 (2 open) [3].

MET is an inclusion eligibility criterion in 1 clinical trial for clear cell sarcoma of soft tissue, of which 1 is open and 0 are closed. Of the trial that contains MET status and clear cell sarcoma of soft tissue as inclusion criteria, 1 is phase 2 (1 open) [3].

RET is an inclusion eligibility criterion in 1 clinical trial for clear cell sarcoma of soft tissue, of which 1 is open and 0 are closed. Of the trial that contains RET status and clear cell sarcoma of soft tissue as inclusion criteria, 1 is phase 2 (1 open) [3].